Testing HMBD-501 for HER3-positive advanced solid tumors
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must weigh at least 88 pounds (40 kg).
- Your cancer must be advanced or metastatic and have the HER3 protein, and you have tried standard treatments or cannot take them.
- You need to be willing to give a fresh tumor sample if your prior HER3 test results are not available.
- You should be able to do daily activities with some help (ECOG performance status 0-2).
- You must agree to use effective contraception during and for 6 months after treatment, if applicable.
- You cannot have had certain cancer treatments within the last 3 weeks, or certain medications that affect liver enzymes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This study tests an investigational drug (KM501) for advanced solid tumors that have HER2 changes. It aims to see if the drug can shrink tumors or slow their growth, and whether it is safe for patients who have run out of standard options.
This trial tests an investigational drug for people with advanced or metastatic HER2-positive solid tumors. The drug is designed to target cancer cells with HER2 and may slow tumor growth.
This Phase 1 trial tests D3L-001 alone in people with HER2-positive advanced solid tumors. It’s mainly looking to see how the drug works and how safe it is in this group.
Hear when a new Melanoma (Skin) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.